These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

385 related items for PubMed ID: 21045153

  • 1. Intranodal vaccination with naked antigen-encoding RNA elicits potent prophylactic and therapeutic antitumoral immunity.
    Kreiter S, Selmi A, Diken M, Koslowski M, Britten CM, Huber C, Türeci O, Sahin U.
    Cancer Res; 2010 Nov 15; 70(22):9031-40. PubMed ID: 21045153
    [Abstract] [Full Text] [Related]

  • 2. Nonspecific CD4(+) T cells with uptake of antigen-specific dendritic cell-released exosomes stimulate antigen-specific CD8(+) CTL responses and long-term T cell memory.
    Hao S, Yuan J, Xiang J.
    J Leukoc Biol; 2007 Oct 15; 82(4):829-38. PubMed ID: 17626150
    [Abstract] [Full Text] [Related]

  • 3. Vaccination with an adenoviral vector encoding the tumor antigen directly linked to invariant chain induces potent CD4(+) T-cell-independent CD8(+) T-cell-mediated tumor control.
    Sorensen MR, Holst PJ, Pircher H, Christensen JP, Thomsen AR.
    Eur J Immunol; 2009 Oct 15; 39(10):2725-36. PubMed ID: 19637230
    [Abstract] [Full Text] [Related]

  • 4. Messenger RNA-based vaccines with dual activity induce balanced TLR-7 dependent adaptive immune responses and provide antitumor activity.
    Fotin-Mleczek M, Duchardt KM, Lorenz C, Pfeiffer R, Ojkić-Zrna S, Probst J, Kallen KJ.
    J Immunother; 2011 Jan 15; 34(1):1-15. PubMed ID: 21150709
    [Abstract] [Full Text] [Related]

  • 5. The boosting effect of co-transduction with cytokine genes on cancer vaccine therapy using genetically modified dendritic cells expressing tumor-associated antigen.
    Ojima T, Iwahashi M, Nakamura M, Matsuda K, Naka T, Nakamori M, Ueda K, Ishida K, Yamaue H.
    Int J Oncol; 2006 Apr 15; 28(4):947-53. PubMed ID: 16525645
    [Abstract] [Full Text] [Related]

  • 6. Therapy of established tumors in a novel murine model transgenic for human carcinoembryonic antigen and HLA-A2 with a combination of anti-idiotype vaccine and CTL peptides of carcinoembryonic antigen.
    Saha A, Chatterjee SK, Foon KA, Celis E, Bhattacharya-Chatterjee M.
    Cancer Res; 2007 Mar 15; 67(6):2881-92. PubMed ID: 17363612
    [Abstract] [Full Text] [Related]

  • 7. Vaccination with liposome--DNA complexes elicits enhanced antitumor immunity.
    U'Ren L, Kedl R, Dow S.
    Cancer Gene Ther; 2006 Nov 15; 13(11):1033-44. PubMed ID: 16841080
    [Abstract] [Full Text] [Related]

  • 8. Noncarrier naked antigen-specific DNA vaccine generates potent antigen-specific immunologic responses and antitumor effects.
    Chen CA, Chang MC, Sun WZ, Chen YL, Chiang YC, Hsieh CY, Chen SM, Hsiao PN, Cheng WF.
    Gene Ther; 2009 Jun 15; 16(6):776-87. PubMed ID: 19357714
    [Abstract] [Full Text] [Related]

  • 9. Antigen-experienced CD4(+) T cells limit naïve T-cell priming in response to therapeutic vaccination in vivo.
    Schiering C, Guarnerio J, Basso V, Muzio L, Mondino A.
    Cancer Res; 2010 Aug 01; 70(15):6161-70. PubMed ID: 20631073
    [Abstract] [Full Text] [Related]

  • 10. The requirement of multimodal therapy (vaccine, local tumor radiation, and reduction of suppressor cells) to eliminate established tumors.
    Kudo-Saito C, Schlom J, Camphausen K, Coleman CN, Hodge JW.
    Clin Cancer Res; 2005 Jun 15; 11(12):4533-44. PubMed ID: 15958639
    [Abstract] [Full Text] [Related]

  • 11. FLT3 ligand enhances the cancer therapeutic potency of naked RNA vaccines.
    Kreiter S, Diken M, Selmi A, Diekmann J, Attig S, Hüsemann Y, Koslowski M, Huber C, Türeci Ö, Sahin U.
    Cancer Res; 2011 Oct 01; 71(19):6132-42. PubMed ID: 21816907
    [Abstract] [Full Text] [Related]

  • 12. Vaccine therapy of established tumors in the absence of autoimmunity.
    Hodge JW, Grosenbach DW, Aarts WM, Poole DJ, Schlom J.
    Clin Cancer Res; 2003 May 01; 9(5):1837-49. PubMed ID: 12738742
    [Abstract] [Full Text] [Related]

  • 13. CD4 T cell help is required for primary CD8 T cell responses to vesicular antigen delivered to dendritic cells in vivo.
    Serre K, Giraudo L, Siret C, Leserman L, Machy P.
    Eur J Immunol; 2006 Jun 01; 36(6):1386-97. PubMed ID: 16673447
    [Abstract] [Full Text] [Related]

  • 14. CD4+ TH1 cells generated by Ii-PADRE DNA at prime phase are important to induce effectors and memory CD8+ T cells.
    Park JY, Jin DH, Lee CM, Jang MJ, Lee SY, Shin HS, Chung YH, Kim KY, Kim SS, Lee WB, Shin YK, Lee WJ, Park YM, Kim D.
    J Immunother; 2010 Jun 01; 33(5):510-22. PubMed ID: 20463596
    [Abstract] [Full Text] [Related]

  • 15. CD4+ T cells are able to promote tumor growth through inhibition of tumor-specific CD8+ T-cell responses in tumor-bearing hosts.
    den Boer AT, van Mierlo GJ, Fransen MF, Melief CJ, Offringa R, Toes RE.
    Cancer Res; 2005 Aug 01; 65(15):6984-9. PubMed ID: 16061684
    [Abstract] [Full Text] [Related]

  • 16. Definition of key variables for the induction of optimal NY-ESO-1-specific T cells in HLA transgene mice.
    Johannsen A, Genolet R, Legler DF, Luther SA, Luescher IF.
    J Immunol; 2010 Sep 15; 185(6):3445-55. PubMed ID: 20733200
    [Abstract] [Full Text] [Related]

  • 17. Intratumoral interleukin-21 increases antitumor immunity, tumor-infiltrating CD8+ T-cell density and activity, and enlarges draining lymph nodes.
    Søndergaard H, Galsgaard ED, Bartholomaeussen M, Straten PT, Odum N, Skak K.
    J Immunother; 2010 Apr 15; 33(3):236-49. PubMed ID: 20445344
    [Abstract] [Full Text] [Related]

  • 18. Eliciting T cell immunity against poorly immunogenic tumors by immunization with dendritic cell-tumor fusion vaccines.
    Wang J, Saffold S, Cao X, Krauss J, Chen W.
    J Immunol; 1998 Nov 15; 161(10):5516-24. PubMed ID: 9820528
    [Abstract] [Full Text] [Related]

  • 19. CpG oligodeoxynucleotides activate dendritic cells in vivo and induce a functional and protective vaccine immunity against a TERT derived modified cryptic MHC class I-restricted epitope.
    Cornet S, Menez-Jamet J, Lemonnier F, Kosmatopoulos K, Miconnet I.
    Vaccine; 2006 Mar 10; 24(11):1880-8. PubMed ID: 16300869
    [Abstract] [Full Text] [Related]

  • 20. Central role of tumor-associated CD8+ T effector/memory cells in restoring systemic antitumor immunity.
    Kilinc MO, Gu T, Harden JL, Virtuoso LP, Egilmez NK.
    J Immunol; 2009 Apr 01; 182(7):4217-25. PubMed ID: 19299720
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 20.